FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 260 filers reported holding FATE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47 | -53.5% | 22,348 | +4.9% | 0.00% | -100.0% |
| Q2 2023 | $101 | -25.7% | 21,303 | -11.0% | 0.00% | 0.0% |
| Q1 2023 | $136 | -42.9% | 23,947 | +1.5% | 0.00% | -50.0% |
| Q4 2022 | $238 | -100.0% | 23,583 | -6.8% | 0.00% | -50.0% |
| Q3 2022 | $567,000 | +87.1% | 25,293 | +107.1% | 0.00% | +100.0% |
| Q2 2022 | $303,000 | -50.4% | 12,214 | -22.6% | 0.00% | -33.3% |
| Q1 2022 | $611,000 | -29.0% | 15,771 | +7.3% | 0.00% | -25.0% |
| Q4 2021 | $860,000 | +21.8% | 14,696 | +23.4% | 0.00% | 0.0% |
| Q3 2021 | $706,000 | -8.8% | 11,913 | +33.6% | 0.00% | 0.0% |
| Q2 2021 | $774,000 | +24.2% | 8,918 | +18.1% | 0.00% | +33.3% |
| Q1 2021 | $623,000 | +11.6% | 7,552 | +23.0% | 0.00% | 0.0% |
| Q4 2020 | $558,000 | – | 6,141 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |